A decision-analytical model shows that everolimus has a favorable budget impact when introduced into the treatment algorithm for metastatic renal cell carcinoma.
Lee Stern, MS
Advertisement
Articles by Lee Stern, MS
Saxagliptin, in combination with metformin, provides a durable, well-tolerated, and cost-effective treatment option for patients with type 2 diabetes mellitus, from a US payer perspective.
Advertisement
Latest Updated Articles
- US Cost-Effectiveness of Saxagliptin in Type 2 Diabetes Mellitus
February 10th 2012
- Budget Impact of Everolimus in Treating Metastatic Renal Cell Carcinoma
November 13th 2012
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First OTC Acetaminophen–Naproxen Combination for 12-Hour Pain Relief
2
Two Weeks In: What the Medicare GLP-1 Bridge Actually Looks Like at the Counter
3
Lilly Prepares for Retatrutide FDA Filing Following Additional Phase 3 Data in Diabetes, CVD
4
Tuberculosis Vaccine May Reshape Brain Immunity and Alter Alzheimer Biomarkers, Early Trial Data Show
5